Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial

BACKGROUND: and objectives The Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 study demonstrated a significant beneficial effect of the vasopressin V2 receptor antagonist tolvaptan on rates of kidney growth and eGFR decline in autosom...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin J Am Soc Nephrol
Autors principals: Torres, Vicente E., Higashihara, Eiji, Devuyst, Olivier, Chapman, Arlene B., Gansevoort, Ronald T., Grantham, Jared J., Perrone, Ronald D., Ouyang, John, Blais, Jaime D., Czerwiec, Frank S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4858477/
https://ncbi.nlm.nih.gov/pubmed/26912543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06300615
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars